Across TCGA pan-cancer cohorts, PARG Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PARG data layer compared with 22 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher PARG Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PARG expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CESC, BLCA, and SARC are the cancer types where PARG Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.547	0.802	.033	12	view →
BLCA	DFS	Median	III,IV	0.121	0.548	.005	12	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	All	0.973	0.828	.017	6	view →
LIHC	DFS	Median	All	0.043	0.527	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: PARG tumor-vs-normal RNA expression · all PARG data types